Epidemiology of invasive fungal infections in Latin America

Current Fungal Infection Reports

Volumn 6, Issue 1, 2012, Pages 23-34

  Sifuentes Osornio, Jose ^a   Corzo León, Dora E ^b   Ponce De León, L Alfredo ^a  

^a Salvador Zubiran National Institute of Medical Science and Nutrition   (Mexico)

^b Salvador Zubiran National Institute of Medical Science and Nutrition   (Mexico)

Author keywords

Argentina; Aspergillosis; Bolivia; Brazil; Candidemia; Central America; Chile; Coccidioidomycosis; Colombia; Costa Rica; Cryptococcosis; Cryptococcus; Cuba; Ecuador; Endemic infections; Epidemiology; Filamentous fungi; Fusariosis; Histoplasmosis; Invasive fungal infections; Latin America; Mexico; Mold fungi; Mucormycosis; Opportunistic infections; Panama; Paracoccidioidomycosis; South America; Uruguay. Paraguay

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POSACONAZOLE; PREDNISONE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIMICROBIAL THERAPY; ARGENTINA; ARTICLE; ASPERGILLOSIS; BRAZIL; CANDIDEMIA; COCCIDIOIDOMYCOSIS; COLOMBIA; CORTICOSTEROID THERAPY; ECUADOR; EPIDEMIC; FUSARIOSIS; GEOGRAPHIC DISTRIBUTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RATE; MEXICO; MORTALITY; MUCORMYCOSIS; MYCOSIS; NONHUMAN; PREVALENCE; SOUTH AMERICAN BLASTOMYCOSIS; SOUTH AND CENTRAL AMERICA; UNITED STATES; URUGUAY; VENEZUELA;

EID: 84862753261     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-011-0081-7     Document Type: Article

References (107)

1. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20:133-63. (Pubitemid 46167771)
2. Nucci M, Queiroz-Telles F, Tobón AM, et al. Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis 2010;51:561-570.
3. Colombo AL, Tobón A, Restrepo A, et al. Epidemiology of endemic systemic fungal infections in Latin America. Med Mycol 2011;49(8):785-98.
4. Sánchez-Alemán MA. Histoplasmosis in travelers [Histoplasmosis del Viajero]. Enf Inf Microbiol. 2009;29:111-6.
5. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50:1091-100.
6. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (TRANS-NET). Clin Infect Dis. 2010;50:1101-11.
7. Lortholary O, Gangneux JP, Sitbon K, et al. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007). Clin Microbiol Infect 2011;April 25. doi:10.1111/j.1469-0691.2011.03548.x
8. Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011;118:1216-24.
9. Negroni R, Duré R, Ortiz Nareto A, et al. Histoplasmosis outbreak in Moron, Buenos Aires province, Argentina [Brote de histoplamosis en la Escuela de Cadetes de la Base Aérea de Morón, Provincia de Buenos Aires, República de Argentina]. Rev Argent Microbiol. 2010;42:254-60.
10. Muñoz B, Martínez MA, Palma G, et al. Molecular characterization of Histoplasma capsulatum isolates from an outbreak in treasure hunters. BMC Infect Dis. 2010;10:264.
11. Laniado-Laborín R. Coccidioidomycosis and other endemic mycoses in Mexico. Rev Iberoam Micol. 2007;24:249-58.
12. Bonifaz A, Vázquez-González D, Perusquía-Ortiz AM. Endemic systemic mycosis: Coccidioidomycosis, histoplasmosis, paracoccidioidomycosis and blastomycosis. J Detsch Dermatol Ges. 2011;9:705-15.
13. van Gelderen de Komaid, Durán EL. Histoplasmosis in the northwestern Argentina II: Prevalence of Histoplasmosis capsulatum y Paracoccidioidomycosis in the population south of Chuscha, Gonzalo y Potrero in the province of Tucuman. Mycopathology 1995;129:17-23.
14. Mata-Essayag S, Colella MT, Roselló A, et al. Histoplasmosis: a study of 158 cases in Venezuela, 2000-2005. Medicine (Baltimore). 2008;87:193-202.
15. Cermeño J, Cermeño J, Godoy G, et al. Epidemiological study of paracoccidioidomycosis and histoplasmosis in a suburb of San Félix city, Bolívar State, Venezuela. Invest Clin 2009;50:213-220.
16. Baddley JW, Winthrop KL, Patkar NM, et al. Geographic distribution of endemic fungal infections among older persons, United States. Emerg Infect Dis. 2011;17:1664-9.
17. Taylor ML, Chávez-Tapia CB, Rojas-Martínez A, et al. Geographical distribution of genetic polymorphism of the pathogen Histoplasma capsulatum isolated from infected bats, captured in a central zone of Mexico. FEMS Immunol Med Microbiol. 2005;42:451-8. (Pubitemid 41247782)
18. Gutierrez ME, Canton A, Connolly P, et al. Detection of Histoplasma capsulatum antigen in Panamanian patients with disseminated histoplasmosis and AIDS. Clin Vaccine Immunol. 2008;15:681-3. (Pubitemid 351967040)
19. Muniz M de M, Morais e Silva Tavares P, Meyer W, et al. Comparison of different DNA-based methods for molecular typing of Histoplasma capsulatum. Appl Environ Microbiol 2010;76:4438-4447.
20. Velasquez-Uribe G, et al. Histoplasmosis in HIV-patients: a cohort study in Medellin, Colombia. [Histoplasmosis en pacientes con SIDA. Un estudio de Cohorte en Medellín, Colombia]. Infectio. 2010;14:S99-S106.
21. Pontes LB, Leitao Tdo M, Lima GG, et al. Clinical characteristics of 134 patients with disseminated histoplasmosis associated with HIV in the estate of Ceara]. Características clínico-evolutivas de 134 pacientes com histoplasmose disseminada associada a SIDA no Estado do Ceará. Rev Soc Bras Med Trop. 2010;43:27-31.
22. Gutiérrez ME, Canton A, Sosa N, et al. Disseminated histoplasmosis in patients with AIDS in Panama: a review of 104 cases. Clin Infect Dis. 2005;40:1199-202. (Pubitemid 40490249)
23. Karimi K, Wheat JL, Connolly P, et al. Differences in histoplasmosis in patients with acquired immunodeficiency syndrome in the United States and Brazil. J Infect Dis. 2002;186:1655-60. (Pubitemid 35379644)
24. Durkin MM, Connolly PA, Karimi K, et al. Pathogenic differences between North American and Latin American strains of Histoplasma capsulatum var capsulatum in experimentally infected mice. J Clin Microbiol. 2004;42:4370-3. (Pubitemid 39296180)
25. Goldani LZ, Aquino VR, Lunardi LW, et al. Two specific strains of Histoplasmosis capsulatum causing mucocutaneous manifestations of histoplasmosis: preliminary analysis of a frequent manifestation of histoplasmosis in southern Brazil. Mycopathology 2009;167:181-186.
26. Bonifaz A, Chang P, Moreno K, et al. Disseminated cutaneous histoplasmosis in acquired immunodeficiency syndrome: report of 23 cases. Clin Exp Dermatol. 2009;34:481-6.
27. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45:807-25. (Pubitemid 47580372)
28. San-Blas G, Burger E. Experimental medical mycological research in Latin America\-a 2000-2009 overview. Rev Iberoam Micol 2011;28:1-25.
29. Bonifaz A, Vázquez-González D, Perusquía-Ortiz AM. Endemic systemic mycosis: coccidioidomycosis, histoplasmosis, paracoccidioidomycosis and blastomycosis. J Dtsch Dermatol Ges. 2011;9:705-15.
30. Cordeiro R de A, Brilhante RS, Rocha MF, et al. Twelve years of coccidioidomycosis in Ceará State, Northeast Brazil: epidemiologic and diagnostic aspects. Diagn Microbiol Infect Dis 2010;66:65-72.
31. Canteros CE, Toranzo A, Ibarra-Camou B, et al. Coccidioidomycosis in Argentina, 1892-2009. Rev Argent Microbiol. 2010;42:261-8.
32. Ampel NM. What's behind the increasing rates of coccidioidomycosis in Arizona and California? Curr Infect Dis Rep. 2010;12:211-6.
33. Tsang C, Anderson SM, Imholte SB, et al. Enhanced surveillance of coccidioidomycosis in Arizona, USA, 2007-2008. Emerg Infect Dis. 2010;16:1738-44.
34. Hector RF, Rutherford GW, Tsang CA, et al. The public health impact of coccidioidomycosis in Arizona and California. Int J Environ Res Public Health. 2011;8:1150-73.
35. Ruddy B, Mayer AP, Ko MG, et al. Coccidioidomycosis in African Americans. Mayo Clin Proc. 2011;86:63-9.
36. Laniado-Laborin R. Expanding understanding of epidemiology of coccidioidomycosis in the western hemisphere. Ann NY Acad Sci. 2007;1111:19-34. (Pubitemid 47573008)
37. Cadena J, Hartzler A, Hsue G, et al. Coccidioidomycosis and tuberculosis coinfection at a tuberculosis hospital: clinical features and literature review. Medicine (Baltimore). 2009;88:66-76.
38. Silva-Hernández AG, Barbachano-Rodríguez E, Alanís-Miranda PA, et al. Tuberculosis and coccidioidomycosis in two patients without immune acquired deficiency [Coexistencia de tuberculosis y coccidioidomicosis en 2 pacientes sin síndrome de inmuno-deficiencia adquirida]. Rev Med Inst Mex Seguro Soc. 2010;48: 447-52.
39. Bercovitch RS, Catanzaro A, Schwartz BS, et al. Coccidioidomycosis during pregnancy: a review and recommendations for management. Clin Infect Dis. 2011;53:363-8.
40. Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis. 2005;41:1217-23. (Pubitemid 41532662)
41. Nucci M, Colombo AL, Queiroz-Telles F. Paracoccidioidomycosis. Curr Fung Infect Rep. 2009;3:15-20.
42. Shankar J, Restrepo A, Clemonds KV, Stevens DA. Hormones and the resistance of women to paracoccidioidomycosis. Clin Microbiol Rev 2011;24:296-313.
43. Tichellio AG, Mangiaterra M, Giusiano G Paracoccidioidomycosis in Formosa province, Argentina [Paracoccidioidomicosis en la provincia de Formosa, Argentina]. Rev Argent Microbiol. 2008; 40:24-9. (Pubitemid 351730262)
44. Batista J Jr, de Camargo ZP, Fernandes GF, et al. Is the geographical origin of a Paracoccidioides brasiliensis isolate important for antigen production for regional diagnosis of paracoccidioidomycosis? Mycoses 2010;53:176-180.
45. Matute D, Quesada-Ocampo LM, Rauscher JT, McEwen JG. Evidence for positive selection in putative virulence factors within the Paracoccidioides brasiliensis species complex. PLos Negl Trop Dis. 2008;2:e296.
46. Pinzan CF, Ruas LP, Casabona-Fortunato AS, et al. Immunological basis for the gender differences in murine Paracoccidioides brasiliensis infection. PLos ONE 2010;5:e10757.
47. de Freitas RM Costa, et al. Pulmonary paracoccidioidomycosis: radiology and clinical-epidemiological evaluation. Rev Soc Bras Med Trop. 2010;43:651-6.
48. Miranda-Paniago AM, Aguilar JI, Aguilar ES, et al. Paracoccidioidomycosis: a clinical and epidemiological study of 422 cases observed in Mato Grosso do Sul [Estudo clínico e epidemiológico de 422 casos observados no Estado de Mato Grosso do Sul.]. Rev Soc Bras Med Trop. 2003;36:455-9.
49. Brazao-Silva MT, Andrade MF, Franco T, et al. Paracoccidioidomycosis: a series of 66 patients with oral lesion from an endemic area. Mycoses. 2011;54:e189-195.
50. Queiroz-Telles F, Goldani LZ, Schlamm HT, et al. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin Infect Dis. 2007;45:1462-9. (Pubitemid 351411876)
51. Prado M, Silva MB, Laurenti R, et al. Mortality due to systematic mycosis as a primary cause of death or in association with AIDS in Brazil: a review from 1996 to 2006. Mem Inst Oswaldo Cruz. 2009;104:513-21.
52. Leroy O, Gangneux JP, Montravers P, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med. 2009;37:1612-8.
53. Corzo DE, Cornejo DP, Sifuentes-Osornio J. Surveillance of Candida spp bloodstream infections and analysis of the risk factors for death: Experience in two National Institutes of Health, 2008-2010 [Vigilancia epidemiológica de las infecciones hema-tógenas por Candida spp. y análisis de los factores de riesgo de muerte: estudio en dos Institutos Nacionales de Salud, 2008-2010]. XXXVI Congr Nal Infect Microbiol Clin, Puebla, Mexico. June 15-18, 2011.
54. Colombo AL, Guimaraes T, Silva LR, et al. Prospective observational study of candidemia in Sao Paulo, Brazil: incidence rate, epidemiology and predictors of mortality. Infect Control Hosp Epidemiol. 2007;28:570-6. (Pubitemid 46814547)
55. Colombo AL, et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol. 2006;44:2816-23. (Pubitemid 44228575)
56. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk-diffusion. J Clin Microbiol. 2010;48: 1366-77.
57. Bruder-Nascimento A, Camargo CH, Sugizaki MF, et al. Species distribution and susceptibility profile of Candida species in a Brazilian public tertiary hospital. BMC Res notes. 2010;3:1-5.
58. González GM, Elizondo M, Ayala J. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3 year (2004-2007) surveillance study. J Clin Microbiol. 2008;46:2902-5.
59. Diaz-Granados CA, Martínez A, Deaza C, Valderrama S. An outbreak of Candida spp. bloodstream infection in a tertiary care center in Bogotá, Colombia. Braz J Infect Dis. 2008;12: 390-4.
60. Rodero L, Davel G, Soria M, et al. Multicenter study of fungemia due to yeast in Argentina [Estudio multicéntrico de fungemias por levaduras en la República de Argentina]. Rev Argent Microbiol. 2005;37:189-95. (Pubitemid 43189505)
61. Giusiano G, Mangiaterra M, Saito VG, et al. Etiology of fungae-mia and catheter colonization in Argentinean paediatrics patients. Mycoses. 2006;49:49-54.
62. Hernández-Dueñas AMR, Vázquez-Larios MR, Soto-Nieto GI, Rivera-Martínez E. Drug susceptibility of yeasts isolated from books from patients of the Instituto Nacional de Cardiologia Ignacio Chavez. [Susceptibilidad de levaduras aisladas de hemo-cultivos en pacientes del Instituto Nacional de Cardiología Ignacio Chávez]. Rev Inv Clin. 2009;61:294-9.
63. Arcaya NM, Mesa LM, Pineda MR, et al. Antifungal drug susceptibility profile among Candida species in blood isolates from patients at the University Hospital, Maracaibo, Venezuela. [Perfil de sensibilidad antifúngica de especies de Candida aisladas de hemocultivos en un hospital Universitario, Maracaibo, Venezuela]. Rev Iberoam Micol. 2006;23:97-100. (Pubitemid 44133528)
64. Panizo MM, Reviákina V, Dolande M, et al. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains. Med Mycol. 2009;47:137-43.
65. Santos PE, Córdoba S, Carrillo-Muñoz A, et al. Epidemiology of fungaemia in apaediatric hospital of high complexity [Epidemio-logía de las fungemias en un hospital pediátrico de alta comple-jidad]. Rev Iberoam Micol. 2010;27:200-2.
66. Reséndiz SJ, Morales AJJ. Risk factors of mortality in fungemias caused by Candida sp. in children. [Factores asociados a mortal-idad por fungemias causadas por Candida sp. en niños]. Bol Med Hosp Infant Mex. 2007;64:91-8.
67. Ajenjo MC, Aquevedo A, Guzmán AM, et al. Epidemiologic profile of invasive candidiasis in patients at the intensive care unit at a university hospital [Perfil epidemiológico de la candidiasis invasora en unidades de pacientes críticos en un hospital universitario]. Rev Chilena Infectol. 2011;28:118-22.
68. Rodríguez AZ, Gómez C de B, Restrepo CA, et al. Antimicrobial susceptibility to fluconazole and voriconazole among Candida spp. isolated in ICU patients from Medellin, Colombia. [Sensibilidad a fluconazol y voriconazol de especies de Candida aisladas de pacientes provenientes de unidades de cuidados intensivos en Medellin, Colombia (2001-2007)]. Rev Iberoam Micol 2010;27:125-129.
69. Nucci M, Alvarado T, Tiraboschi N, et al. Epidemiology of candidemia in Latin America: Preliminary results of a prospective laboratory-based survey. 50th ICAAC, Boston, Mass, September 2-15, 2010.
70. Lin X. Cryptococcus neoformans: Morphogenesis, infection and evolution. Infect Genet Evol. 2009;9:401-16.
71. Castañon-Olivares LR, Martínez KM, Cruz RM, et al. Genotyp-ing of Mexican Cryptococcus neoformans and C. gatti isolates by PCR-fingerprinting. Med Mycol. 2009;47:713-21.
72. Quinet-Leiman BC, Jorge-Koifman R. Official information systems for cryptococcal meningitis, state of Rio de Janeiro, Southeastern Brazil. Rev Saúde Pública. 2009;43:1-4.
73. da Cunha Colombo ER, Mora DJ, Silva-Vergara ML. Immune reconstitution inflammatory syndrome (IRIS) associated with Cryptococcus neoformans infection in AIDS patients. Mycoses. 2011;54:e178-82.
74. Lizarazo J, Linares M, de Bedout C, et al. Clinical and epidemiologic study of cryptococcosis in Colombia: a nine-year national survey 1997-2005 [Estudio clínico y epidemiológico de la crip-tococcosis en Colombia: resultados de nueve años de la encuesta nacional, 1997-2005]. Biomédica. 2007;27:94-109. (Pubitemid 351836112)
75. Meyer W, Castañeda A, Jackson S, et al. Molecular typing of Iberoamerican Cryptococcus neoformans Isolates. Emerg Infect Dis. 2003;9:189-95. (Pubitemid 36231789)
76. Leal AL, Faganello J, Fuentefria AM, et al. Epidemiological profile of cryptococcal meningitis patients in Rio Grande do Sul, Brazil. Mycopathologia. 2008;166:71-5.
77. Lindenberg A, Chang M, Paniago A, et al. Clinical and epidemiological features of 123 cases of cryptococcosis in Mato Grosso do Sul, Brazil. Rev Inst Med Trop Sao Paulo. 2008;50:75-8. (Pubitemid 351744066)
78. Pappalardo M, Paschoal R, Melhem M. AIDS-associated central nervous system cryptococcosis: a Brazilian case study. AIDS. 2007;21:1971-3.
79. Ribeiro LC, Hahn RC, Favalessa OC. Systemic mycosis: factors associated with death among patients infected with human immunodeficiency virus Cuiaba, state of Mato Grosso, Brazil, 2005-2008 [Micoses sistemicas: fatores associados ao obito em pacientes com infecção pelo vírus da imunodeficiência humana, Cuiabá, Estado de Mato Grosso, 2005-2008.]. Rev Soc Bras Med Trop. 2009;42:698-705.
80. Pfaller MA, Messer SA, Boyken L, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol. 2005;43:2163-7. (Pubitemid 40656221)
81. Rabagliati R, Fuentes LG, Guzman DAM, et al. Fungal invasive disease in onco-hematologic patients and recipients of bone-marrow transplantation [Enfermedad fúngica invasora en pacientes hemato-oncológicos y receptores de trasplante de precursores hematopoyé-ticos bajo la perspectiva de los conceptos diagnósticos de EORTC/MSG]. Rev Chilena Infect. 2009;26:212-9.
82. Davel G, Canteros CE. Current situation of the mycosis in Argentina [Situación de las micosis en la República de Argentina]. Rev Argent Microbiol. 2007;39:28-33.
83. Villarroel M, Aviles CL, Silva P, et al. Risk factors associated with invasive fungal disease in children with cancer and febrile neutropenia. Pediatr Infect Dis J 2010;29:816-821.
84. Rodrigues-Aquino V, Vercosa EB, Falhauber G, et al. Distribution of filamentous fungi causing invasive fungal disease at the Haematological Unit, Hospital de clínicas de Porto Alegre, Brazil. Braz J Infect Dis. 2010;14:277-80.
85. Cruz R, Piontelli LE. Invasive fungal disease in patients from five hospitals in the Valparaiso region, Chile: 2004 to 2009. [Enfermedad fúngica invasora en pacientes de 5 hospitales de la Región de Valparaíso, Chile. 2004-2009]. Rev Chilena Infectol. 2011;28:123-9.
86. Carvalho-Dias VM, Sola CB, Cunha CA, et al. Invasive aspergillosis in hematopoietic stem cell transplant recipients. Braz J Infect Dis. 2008;12:385-9.
87. Nucci M, Noùer SA, Grazziutti, et al. Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of Aspergillosis, and implications for studying novel therapies. Clin Infect Dis. 2010;51:1273-80.
88. Nouér S, Nucci M, Kumar NS, et al. Earlier response assessment in invasive Aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. Clin Infect Dis. 2011;53:671-6.
89. Frías-De León MG, Zavala-Ramirez M, Cordoba S, et al. Pheno-typic characteristic of Aspergillus section fumigate from different geographic origins and their relationships with genotypic characteristics. BMC Infect Dis. 2011;11:116.
90. Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J Clin Microbiol. 2006;44:1782-7. (Pubitemid 43726269)
91. Nunes Mdo C, Barbosa FB, Gomes GH, et al. Fatal right-sided endocarditis caused by Fusarium in an immunocompromised patient: a case report. Mycoses. 2011;54:460-2.
92. Nucci M, Marr KA, Queiroz-Telles F, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2004;38:1237-42. (Pubitemid 38608564)
93. Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised host: implications for diagnosis and management. Clin Infect Dis. 2002;35:909-20. (Pubitemid 35178307)
94. Córdoba S, Rodero L, Vivot W, et al. In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. Int J Antimicrob Agents. 2008;31:171-4.
95. Yun-Sun H, Singh N. Mucormycosis: its contemporary face and management strategies. Lancet Infect Dis. 2011;11:301-11.
96. Arce-Salinas CA, Pérez-Silva E. Mucormycosis complication in systemic lupus erythematosus. Lupus. 2010;19:985-8.
97. Ayala-Gaytán JJ, Petersen-Morfín S, Guajardo-Lara CE, et al. Cutaneous zygomycosis in immunocompetent patients in México. Mycoses. 2010;53:538-40.
98. Severo LC, Oliveira FD, Dreher R, et al. Zygomycosis: a report of eleven cases and a review of the Brazilian literature. Rev Iberoam Micol. 2002;19:52-6. (Pubitemid 34475510)
99. Ramírez C, Hernández AF, Méndez V, et al. Case report of mucormycosis in a patient with secondary methimazole-induced agranulocytosis [Mucormicosis en un paciente con agranulocito-sis secundaria a metimazol. Informe de un caso.]. Gac Med Mex. 2009;145:235-8.
100. Auxiliadora-Martínez M, Alkmim-Teixeira GC, Machado-Viana J, et al. Meningoencephalitis caused by a zygomycete fungus (Basidiobolus) associated with septic shock in an immunocom-petent patient: 1-year follow-up after treatment. Braz J Med Biol Res. 2010;43:794-8.
101. Tapia EO, Chahín AC, Concha FC. Primary cutaneous mucor-mycosis: report of two cases and review. [Mucormicosis cutánea primaria: a propósito de 2 casos. Revisión de la literatura]. Rev Chilena Infectol. 2011;28:269-73.
102. Passos XS, Sales WS, Maciel PJ, et al. Nosocomial invasive infection caused by Cunninghamella bertholletiae: case report. Mycopathologia. 2006;161:33-5. (Pubitemid 43042219)
103. Saravia-Flores M, Guaran DM, Argueta V. Invasive cutaneous infection, caused by Apophysomyces elegans associated with a spider bite. Mycoses. 2009;53:259-61.
104. Cortés JA, Reyes P, Gómez C, et al. Fungal bloodstream infection in tertiary care hospital in Colombia. Rev Iberoam Micol. 2011;28:74-8.
105. Pérez C, Dolande M, Moya M, et al. Cryptococcus neoformans, Cryptococcus gatti. Serotypes in Venezuela. Mycopathologia. 2008;166:149-53.
106. Souza LK, Souza Junior AH, Costa CR, et al. Molecular typing and antifungal susceptibility of clinical and environmental Cryp-tococcus neoformans species complex isolates in Goiania, Brazil. Mycoses. 2008;53:62-7.
107. Trilles L, Lazera Mdos S, Wanke B, et al. Regional pattern of the molecular types of Cryptococcus neoformans and Cryptococcus gattii in Brazil. Mem Inst Oswaldo Cruz. 2008;103:455-62.